1. Home >
  2. M&A >
  3. Growth Capital >
  4. United States >
  5. Pennsylvania >
  6. HBM Partners Invests In Fore Biotherapeutics

Investment Summary

HBM Partners Invests In Fore Biotherapeutics

On February 22, 2021, private equity firm HBM Partners invested in life science company Fore Biotherapeutics

Investment Highlights
  • This is HBM Partners’ 47th transaction in the Life Science sector.
  • This is HBM Partners’ 36th transaction in the United States.
  • This is HBM Partners’ 3rd transaction in Pennsylvania.

Investment Summary
Date 2021-02-22
Target Fore Biotherapeutics
Sector Life Science
Investor(s) HBM Partners
Deal Type Growth Capital

Target

Fore Biotherapeutics

Philadelphia, Pennsylvania, United States
Fore Biotherapeutics is a biotechnology company developing compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Fore Biotherapeutics’ lead program, PLX-8394, is in clinical development for BRAF-mutated tumors without approved therapies. Fore Biotherapeutics was founded in 2011 and is based in Philadelphia, Pennsylvania.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

HBM Partners

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 54 of 65
Sector: Life Science M&A 47 of 56
Type: Growth Capital M&A Deals 6 of 7
State: Pennsylvania M&A 3 of 4
Country: United States M&A 36 of 44
Year: 2021 M&A 7 of 15
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-11 Antiva Biosciences

Redwood City, California, United States

Antiva Biosciences is a developing novel topical therapies to treat pre-cancerous lesions caused by HPV, before they progress to cervical cancer. Antiva Biosciences was founded in 2012 and is based in Redwood City, california.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-01 Parabilis Medicines

Cambridge, Massachusetts, United States

Parabilis Medicines is a biopharmaceutical company with a mission to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable. The company is pioneering the discovery, development and commercialization of Helicon peptides, a new drug modality that uniquely combines the cell-permeability and oral dosing optionality of traditional small molecule drugs with the high specificity, broad target accessibility and rapid discovery arc of monoclonal antibody drugs. Parabilis Medicines was founded in 2016 and is based in Cambridge, Massachusetts.

Buy -
Mergr

Solution for

Product

Company

Legal